
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines Ltd is positioned for sustained long-term growth, underpinned by strong market preference for its lead product, Brukinsa, which is projected to reach peak sales of approximately $7.1 billion by 2034. With sonrotoclax demonstrating enhanced efficacy and safety profiles compared to competitors, the company's growth dynamics are further supported by an expected $3.4 billion peak sales contribution from Brukinsa and additional revenues bolstered by other therapeutic assets. The company's ongoing strategic initiatives in physician outreach and competitive contracting are anticipated to drive physician engagement, positioning BeOne Medicines towards achieving profitable operations and positive free cash flow by 2025.
Bears say
BeOne Medicines Ltd faces a negative outlook primarily due to the potential for slower-than-expected uptake of its commercial products, compounded by the risk of unsuccessful clinical trials and adverse regulatory decisions, which could limit the company's market potential. Additionally, significant cash burn associated with its pipeline raises concerns about the viability of developing marketable drugs, especially in a highly competitive oncology market where product differentiation is critical. Furthermore, geopolitical risks, along with uncertainties surrounding intellectual property protection, could further undermine the company’s competitive positioning and financial stability.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares